The importance of identifying and validating prognostic factors in oncology
- PMID: 20494694
- PMCID: PMC2929829
- DOI: 10.1053/j.seminoncol.2010.04.001
The importance of identifying and validating prognostic factors in oncology
Abstract
Prognosis plays a vital role in patient management and decision making. The assessment of prognostic factors, which relate baseline clinical and experimental covariables to outcomes, is one of the major objectives in clinical research. Historically, the impetus for the identification of prognostic factors has been the need to accurately estimate the effect of treatment adjusting for these variables. In oncology, the variability in outcome may be related to prognostic factors rather than to differences in treatments. In this article, we begin with a brief review of prognostic factors, and then subsequently offer a general discussion of their importance. Next, we describe the significance of study design before presenting various modeling approaches for identifying these factors and discussing the relative values of the different approaches. We illustrate the concepts within the framework of published and ongoing phase III trials in oncology.
Copyright 2010 Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials.Support Care Cancer. 2012 Jun;20(6):1317-25. doi: 10.1007/s00520-011-1219-4. Epub 2011 Jul 1. Support Care Cancer. 2012. PMID: 21720747
-
Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.Circ Res. 2019 Jul 19;125(3):265-281. doi: 10.1161/CIRCRESAHA.119.314951. Epub 2019 Jul 18. Circ Res. 2019. PMID: 31318648 Free PMC article. Review.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170 Review.
Cited by
-
Prognostic Value of Hematological Parameters in Oral Squamous Cell Carcinoma.Cancers (Basel). 2023 Oct 31;15(21):5245. doi: 10.3390/cancers15215245. Cancers (Basel). 2023. PMID: 37958419 Free PMC article.
-
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation.Int J Mol Sci. 2023 Aug 25;24(17):13219. doi: 10.3390/ijms241713219. Int J Mol Sci. 2023. PMID: 37686024 Free PMC article. Review.
-
Developing a Core Outcome Set for Prognostic Research in Palliative Cancer Care: Protocol for a Mixed Methods Study.JMIR Res Protoc. 2023 Sep 1;12:e49774. doi: 10.2196/49774. JMIR Res Protoc. 2023. PMID: 37656505 Free PMC article.
-
What outcomes do studies use to measure the impact of prognostication on people with advanced cancer? Findings from a systematic review of quantitative and qualitative studies.Palliat Med. 2023 Oct;37(9):1345-1364. doi: 10.1177/02692163231191148. Epub 2023 Aug 10. Palliat Med. 2023. PMID: 37586031 Free PMC article. Review.
-
Combination of neutrophil/lymphocyte ratio and albumin/bilirubin grade as a prognostic predictor for hepatocellular carcinoma patients undergoing curative hepatectomy.BMC Gastroenterol. 2023 May 19;23(1):162. doi: 10.1186/s12876-023-02804-5. BMC Gastroenterol. 2023. PMID: 37208618 Free PMC article.
References
-
- Altman DG. Studies investigating prognostic factors: conduct and evaluation. In: Gospodarowicz MK, O’Sullivan B, Sobin H, editors. Prognostic Factors in Cancer. 3rd ed. Hoboken, NJ: Wiley-Liss; 2006. pp. 39–54.
-
- Harrell FE, Jr, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3:143–152. - PubMed
-
- Schumacher M, Hollander N, Schwarzer G, Sauerbrei W. Prognostic factor studies. In: Crowley J, Ankerst DP, editors. Handbook of Statistics in Clinical Oncology. 2nd ed. Boca Raton, FL: Chapman & Hall; 2006. pp. 289–333.
-
- Eastham JA, Kelly WK, Grossfeld GD, et al. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urol. 2003;62 Suppl 1:55–62. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
